Xolremdi
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Mavorixafor
- Made by
- Norgine B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (XOLREMDI). It describes the substance, not this exact product.
Mavorixafor is an orally bioavailable CXCR4 antagonist that blocks the binding of the CXCR4 ligand, stromal-derived factor-1α (SDF-1α)/CXC Chemokine Ligand 12 (CXCL12).
SDF-1/CXCR4 plays a role in trafficking and homing of leukocytes to and from the bone marrow compartment.
Effect of Food High Fat Meal: Mavorixafor C max decreased by 66% and AUC decreased by 55% following single-dose administration of XOLREMDI 400 mg with a high‑fat meal (1000 calories, 50% fat) to healthy subjects.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-11-12
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Norgine B.V. |
|---|---|
| Active substance | Mavorixafor |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03AX24 · Cancer treatments and immune-system medicines |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-04-27 |
| Last updated by the regulator | 2026-09-14 |
| EMA product number | EMEA/H/C/006496 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).